Centessa Pharmaceuticals
Prezzo: 39.72Società e modello di business
Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. Its core products include a pipeline of drug candidates targeting various diseases, primarily in oncology and rare diseases. The company operates through multiple business segments, emphasizing research and development to advance its therapeutic offerings. Major revenue sources are expected to stem from future product launches and collaborations with other pharmaceutical entities.
Profilo di investimento
The investment profile of Centessa Pharmaceuticals is more aligned with growth investors, given its focus on developing new therapies and the potential for future revenue generation. However, the high risk associated with its clinical-stage status may deter conservative investors. The stock may appeal to those with a longer investment horizon, as the company seeks to establish its market presence.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- -1.78 Rischio
- Sorpresa EPS
- -36.8% peggio del previsto
- Volatilità 20g
- 0.2% stabile
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-09 02:36 | Mantieni | Vendi | Weak fundamentals and high risk limit upside potential. |
| 2026-06-01 02:34 | Vendi | Mantieni | Weak fundamentals and high volatility signal caution. |
| 2026-05-16 02:53 | Mantieni | Vendi | Weak fundamentals and high volatility raise concerns. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-04-20 09:12 | Wells Fargo | Rating peggiorato | — → 42 | 39.66 |
| 2026-02-23 21:07 | Wolfe Research | Aggiorna | — → 40 | 25.49 |
| 2026-01-29 14:25 | Truist Financial | Target alzato | 33 → 38 | 24.73 |
Ancora nulla